These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 30563749)

  • 1. Isogenic cell models of cystic fibrosis-causing variants in natively expressing pulmonary epithelial cells.
    Valley HC; Bukis KM; Bell A; Cheng Y; Wong E; Jordan NJ; Allaire NE; Sivachenko A; Liang F; Bihler H; Thomas PJ; Mahiou J; Mense M
    J Cyst Fibros; 2019 Jul; 18(4):476-483. PubMed ID: 30563749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Correctors and Potentiators Enhance Translational Readthrough in CFTR Nonsense Mutations.
    Mutyam V; Sharma J; Li Y; Peng N; Chen J; Tang LP; Falk Libby E; Singh AK; Conrath K; Rowe SM
    Am J Respir Cell Mol Biol; 2021 May; 64(5):604-616. PubMed ID: 33616476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of Cas9 and Cas12a CRISPR editing methods to correct the W1282X-CFTR mutation.
    Santos L; Mention K; Cavusoglu-Doran K; Sanz DJ; Bacalhau M; Lopes-Pacheco M; Harrison PT; Farinha CM
    J Cyst Fibros; 2022 Jan; 21(1):181-187. PubMed ID: 34103250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor.
    Xue X; Mutyam V; Tang L; Biswas S; Du M; Jackson LA; Dai Y; Belakhov V; Shalev M; Chen F; Schacht J; J Bridges R; Baasov T; Hong J; Bedwell DM; Rowe SM
    Am J Respir Cell Mol Biol; 2014 Apr; 50(4):805-16. PubMed ID: 24251786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonsense-mediated RNA Decay Pathway Inhibition Restores Expression and Function of W1282X CFTR.
    Keenan MM; Huang L; Jordan NJ; Wong E; Cheng Y; Valley HC; Mahiou J; Liang F; Bihler H; Mense M; Guo S; Monia BP
    Am J Respir Cell Mol Biol; 2019 Sep; 61(3):290-300. PubMed ID: 30836009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of adenine base editing and homology-independent targeted integration strategies to correct the cystic fibrosis causing variant, W1282X.
    Mention K; Cavusoglu-Doran K; Joynt AT; Santos L; Sanz D; Eastman AC; Merlo C; Langfelder-Schwind E; Scallan MF; Farinha CM; Cutting GR; Sharma N; Harrison PT
    Hum Mol Genet; 2023 Nov; 32(23):3237-3248. PubMed ID: 37649273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive Analysis of Combinatorial Pharmacological Treatments to Correct Nonsense Mutations in the CFTR Gene.
    Venturini A; Borrelli A; Musante I; Scudieri P; Capurro V; Renda M; Pedemonte N; Galietta LJV
    Int J Mol Sci; 2021 Nov; 22(21):. PubMed ID: 34769402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin.
    Linde L; Boelz S; Nissim-Rafinia M; Oren YS; Wilschanski M; Yaacov Y; Virgilis D; Neu-Yilik G; Kulozik AE; Kerem E; Kerem B
    J Clin Invest; 2007 Mar; 117(3):683-92. PubMed ID: 17290305
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54.
    Rowe SM; Sloane P; Tang LP; Backer K; Mazur M; Buckley-Lanier J; Nudelman I; Belakhov V; Bebok Z; Schwiebert E; Baasov T; Bedwell DM
    J Mol Med (Berl); 2011 Nov; 89(11):1149-61. PubMed ID: 21779978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small-molecule eRF3a degraders rescue CFTR nonsense mutations by promoting premature termination codon readthrough.
    Lee RE; Lewis CA; He L; Bulik-Sullivan EC; Gallant SC; Mascenik TM; Dang H; Cholon DM; Gentzsch M; Morton LC; Minges JT; Theile JW; Castle NA; Knowles MR; Kimple AJ; Randell SH
    J Clin Invest; 2022 Sep; 132(18):. PubMed ID: 35900863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A G542X cystic fibrosis mouse model for examining nonsense mutation directed therapies.
    McHugh DR; Steele MS; Valerio DM; Miron A; Mann RJ; LePage DF; Conlon RA; Cotton CU; Drumm ML; Hodges CA
    PLoS One; 2018; 13(6):e0199573. PubMed ID: 29924856
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Functional rescue of c.3846G>A (W1282X) in patient-derived nasal cultures achieved by inhibition of nonsense mediated decay and protein modulators with complementary mechanisms of action.
    Laselva O; Eckford PD; Bartlett C; Ouyang H; Gunawardena TN; Gonska T; Moraes TJ; Bear CE
    J Cyst Fibros; 2020 Sep; 19(5):717-727. PubMed ID: 31831337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced expression of Tis7/IFRD1 protein in murine and human cystic fibrosis airway epithelial cell models homozygous for the F508del-CFTR mutation.
    Blanchard E; Marie S; Riffault L; Bonora M; Tabary O; Clement A; Jacquot J
    Biochem Biophys Res Commun; 2011 Aug; 411(3):471-6. PubMed ID: 21723850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exon-skipping antisense oligonucleotides for cystic fibrosis therapy.
    Kim YJ; Sivetz N; Layne J; Voss DM; Yang L; Zhang Q; Krainer AR
    Proc Natl Acad Sci U S A; 2022 Jan; 119(3):. PubMed ID: 35017301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study.
    Sermet-Gaudelus I; Renouil M; Fajac A; Bidou L; Parbaille B; Pierrot S; Davy N; Bismuth E; Reinert P; Lenoir G; Lesure JF; Rousset JP; Edelman A
    BMC Med; 2007 Mar; 5():5. PubMed ID: 17394637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Novel G542X CFTR Rat Model of Cystic Fibrosis Is Sensitive to Nonsense Mediated Decay.
    Sharma J; Abbott J; Klaskala L; Zhao G; Birket SE; Rowe SM
    Front Physiol; 2020; 11():611294. PubMed ID: 33391025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis.
    Awatade NT; Uliyakina I; Farinha CM; Clarke LA; Mendes K; Solé A; Pastor J; Ramos MM; Amaral MD
    EBioMedicine; 2015; 2(2):147-53. PubMed ID: 26137539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sheep models of F508del and G542X cystic fibrosis mutations show cellular responses to human therapeutics.
    Viotti Perisse I; Fan Z; Van Wettere A; Liu Y; Leir SH; Keim J; Regouski M; Wilson MD; Cholewa KM; Mansbach SN; Kelley TJ; Wang Z; Harris A; White KL; Polejaeva IA
    FASEB Bioadv; 2021 Oct; 3(10):841-854. PubMed ID: 34632318
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene-specific nonsense-mediated mRNA decay targeting for cystic fibrosis therapy.
    Kim YJ; Nomakuchi T; Papaleonidopoulou F; Yang L; Zhang Q; Krainer AR
    Nat Commun; 2022 May; 13(1):2978. PubMed ID: 35624092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting G542X CFTR nonsense alleles with ELX-02 restores CFTR function in human-derived intestinal organoids.
    Crawford DK; Mullenders J; Pott J; Boj SF; Landskroner-Eiger S; Goddeeris MM
    J Cyst Fibros; 2021 May; 20(3):436-442. PubMed ID: 33558100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.